Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an announcement.
Zymeworks announced the acceptance of six abstracts for presentation at the AACR Annual Meeting, highlighting their advancements in T cell engager and antibody-drug conjugate platforms. The company showcased promising preclinical data for ZW209, a trispecific T cell engager, and ZW327, an antibody-drug conjugate, both demonstrating potential efficacy and safety in treating various cancers. These developments underscore Zymeworks’ commitment to advancing innovative therapies for challenging cancer types, potentially improving outcomes for patients with limited treatment options.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics to improve the standard of care for diseases that are difficult to treat, such as cancer, inflammation, and autoimmune diseases.
YTD Price Performance: -11.71%
Average Trading Volume: 517,738
Technical Sentiment Signal: Sell
Current Market Cap: $892.3M
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.